Natural occurrence of drug resistance mutations to the HIV‐1 capsid inhibitor lenacapavir
HIV Medicine, EarlyView.Abstract Aims Lenacapavir (LEN) is a first‐in‐class HIV‐1 capsid inhibitor. We investigated the natural occurrence of LEN drug resistance mutations (DRM) in HIV‐1 sequences from LEN treatment‐naïve individuals. Methods We analysed all available HIV‐1 capsid sequences (n = 21 646) from individuals never exposed to LEN from the Los Alamos National ...
A. Weibull Wärnberg +3 more
wiley +1 more source
EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
Pakistan Armed Forces Medical Journal, 2021 Objective: To study the tolerability and efficacy of dolutegravir in naïve and experienced patients, their management and outcome. Study Design: Cross sectional study. Place and Duration of Study: Ruth KM Pfau Civil Hospital, Karachi Pakistan, from
Farzana Batool +5 more
doaj
Solid organ transplantation in people with HIV: Outcomes, obstacles and opportunities
HIV Medicine, EarlyView.Abstract Objective People with HIV experience disparate access to solid organ transplantation (SOT), despite mounting evidence for comparable outcomes. This review aims to understand the outcomes following SOT, obstacles to SOT and opportunities to improve access and outcomes following SOT.
David W. J. Griffin +3 more
wiley +1 more source
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
Infection and Drug Resistance, 2010 Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj
Integrase inhibitor‐based treatment in clinical practice
Journal of the International AIDS Society, 2010 7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow ...
M Feasi +5 more
openaire +2 more sources
Rapid Communications in Mass Spectrometry, Volume 39, Issue 21, 15 November 2025.ABSTRACT Context Therapeutic drug monitoring (TDM) involves the collection of biological samples such as blood, plasma, urine, and saliva. The most commonly used biological matrix for the detection of drugs is either blood or plasma, as they are widely accepted by the regulatory authorities.
Arpita Sathyanarayanan +2 more
wiley +1 more source
2-Mercaptobenzenesulphonamides as Novel Inhibitors of Human Immunodeficiency virus Type 1 Integrase and Replication [PDF]
, 1997 Nouri Neamati +5 more
openalex +1 more source
Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids
Molecules, 2015 HIV integrase, encoded at the 3′-end of the HIV pol gene, is essential for HIV replication. This enzyme catalyzes the incorporation of HIV DNA into human DNA, which represents the point of “no-return” in HIV infection.
V. Nair, Maurice O Okello
semanticscholar +1 more source
Glia, Volume 73, Issue 10, Page 1967-1988, October 2025.Main Points Pre‐exposure prophylaxis (PrEP) inhibits oligodendrocyte differentiation PrEP inhibits oligodendrocyte differentiation through lysosome deacidification Acidic nanoparticles prevent PrEP‐induced inhibition of oligodendrocyte differentiation ABSTRACT A disproportionate percentage of adolescents are diagnosed with human immunodeficiency virus (
Caela C. Long +6 more
wiley +1 more source
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase [PDF]
, 2000 Amy S. Espeseth +11 more
openalex +1 more source